Cannabis stocks surge after reports of Trump planning to ease federal restrictions
Reclassification to Schedule III could boost medical research, ease banking, and lift cannabis sector growth to 20% annually, with stocks rising over 30% on news.
- On Dec. 10, President Donald Trump discussed reclassifying marijuana and reports say he plans an executive order directing federal agencies to move it to Schedule III.
- Federal law currently treats cannabis as Schedule I, blocking research, interstate commerce and banking access, while the industry has languished amid regulatory uncertainty, oversupply and limited financing in recent years.
- Traders piled into cannabis ETFs and major stocks, pushing heavy-volume rallies Friday as the AdvisorShares Pure US Cannabis ETF jumped more than 50% to around $5.71, Tilray Brands traded at $11.85 up $3.42, and Aurora Cannabis climbed nearly 18% to about $5.35.
- Rescheduling would remove the 280E tax penalty and could lift after-tax profits by 40% to 70%, ease research and pharmacy dispensing with Medicare and Medicaid coverage, though no final decisions exist and Drug Enforcement Administration rulemaking is required.
- Rescheduling would stop short of federal legalization, which U.S. Congress must enact, and analysts say it could double industry growth to 20% annually but delay effects 12 to 18 months; despite Friday’s bonanza, broad cannabis indices remain down more than 90% from pandemic peaks.
15 Articles
15 Articles
The actions of Canadian cannabis companies have increased following reports that US President Donald Trump is considering relaxing federal restrictions on cannabis.
Big shift in US drug policy? Trump likely to ease curbs on marijuana use and sales, pot stocks fly high
President Trump may push to reclassify marijuana from Schedule I to Schedule III, easing restrictions on its sale and use. This development sent pot shares soaring.
Cannabis stocks surge after reports of Trump planning to ease federal restrictions
TORONTO - Shares in Canada's cannabis companies surged after reports U.S. President Donald Trump is planning to ease federal restrictions on the drug.
Coverage Details
Bias Distribution
- 67% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium











